Trial Profile

A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) in Patients With Relapsing Multiple Sclerosis [AIOLOS]

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Mar 2025 According to a Novartis Media Release, data from the study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego from April 5-9, 2025.
14 Jan 2025 Status changed from recruiting to active, no longer recruiting.
18 Apr 2024 Interim Results assessing differences between patients receiving ofatumumab as first-line treatment (approx. 240 patients) and patients having switched to ofatumumab (approx. 300 patients) with regards to baseline criteria, effectiveness, safety, and tolerability presented at the 76th Annual Meeting of the American Academy of Neurology 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com